CareDx to Acquire Cancer-Test Maker Naveris for Up to $260M, Adding NavDx to Specialty Oncology Lineup

CareDx, Inc. agreed to acquire viral-cancer diagnostics company Naveris, Inc. for $160 million in cash plus up to $100 million in earnouts tied to revenue milestones, in a Form 8-K filed April 28, 2026.

CareDx, Inc. (Nasdaq: CDNA) agreed to acquire Naveris, Inc. for $160 million in cash plus up to $100 million in earnouts tied to revenue milestones. The Brisbane, California-based transplant-diagnostics company disclosed the deal in a Form 8-K filed April 28, 2026. Naveris is a privately held precision oncology business whose flagship NavDx test detects fragments of viral DNA released from HPV-driven tumors, and the acquisition is the first time CareDx has stepped beyond its core transplant franchise into specialty oncology testing.

The transaction is structured as a reverse triangular merger. CareDx (Nasdaq: CDNA) will use a wholly owned Delaware subsidiary called Nautilus Merger Sub, Inc. to merge into Naveris, with Naveris surviving as a wholly owned subsidiary of CareDx. Shareholder Representative Services LLC is acting as representative for the Naveris securityholders. The structure and terms come from the Form 8-K filed with the Securities and Exchange Commission on April 28, 2026 and the full Agreement and Plan of Merger filed as Exhibit 2.1 to that 8-K.

Deal Economics: $160 Million Up Front, $100 Million Contingent

The 8-K reports that at closing, CareDx will pay Naveris equityholders “an aggregate $160.0 million in cash, subject to certain customary adjustments specified in the Merger Agreement, including for Naveris’ cash, indebtedness, transaction expenses and net working capital.” Of that closing consideration, $5.0 million will be deposited into an escrow account to secure post-closing purchase price adjustments. The escrow is the standard mechanism by which the acquirer holds back a portion of cash to cover any downward true-ups to net working capital or indebtedness once final closing-date balances are computed.

Beyond the closing payment, Naveris equityholders are eligible to receive “up to $100.0 million in additional cash consideration contingent upon the achievement of specified revenue-based milestones in respect of fiscal years ending December 31, 2026 and December 31, 2027.” The 8-K does not disclose the specific revenue thresholds or how the $100 million is split across the two milestone years. Those details are protected as commercially sensitive and may surface in the proxy or in the merger agreement disclosure schedules if those are filed in a subsequent amendment.

Total potential consideration is therefore $260 million, of which 62 percent is paid at closing and 38 percent is deferred and contingent. Earnouts of this kind are common in life-sciences acquisitions of commercial-stage diagnostics where the seller’s revenue trajectory is the primary value driver. They align the acquirer’s check size with realized growth and they preserve upside for the founders and venture investors of the target.

The Asset Being Bought: NavDx and the TTMV-DNA Platform

Naveris was founded in 2017 and operates as a portfolio company of B-FLEXION Life Sciences. It is commercial-stage, with approximately 100 employees and more than 130,000 NavDx tests performed to date according to the press release announcing the deal. NavDx is a blood-based liquid biopsy test that measures Tumor Tissue Modified Viral DNA, or TTMV-DNA, fragments of viral DNA released from tumor cells into the bloodstream. The test is used to monitor patients with cancers driven by human papillomavirus, primarily head and neck cancer and anal cancer.

The clinical workflow is molecular residual disease, or MRD, surveillance. After a patient completes treatment for an HPV-driven cancer, NavDx is used to track whether residual tumor DNA persists in circulation, which can indicate microscopic disease that imaging cannot yet detect. Detecting recurrence earlier is the value proposition. NavDx has held Medicare coverage since 2023, which is the gating commercial reimbursement event for any U.S. clinical diagnostics business; without Medicare, the test cannot scale.

The financial profile of the acquired business is unusual for a venture-backed diagnostics company. Naveris reported approximately $34 million of unaudited 2025 revenue. In the first quarter of 2026, Naveris reported approximately $12 million of revenue, 65 percent gross margin, and a net operating loss of just $0.2 million. Implied annualized 2026 first-quarter revenue is around $48 million, and a near-breakeven operating result at that scale is what drives the acquirer’s stated assumption that the deal will not impact CareDx’s 2026 Adjusted EBITDA guidance. CareDx forecasts Naveris revenue to grow 30 to 40 percent annually for the next three years.

The Number That Matters: $4.5 Billion Total Addressable Market

CareDx pegged the addressable market for viral-mediated cancer surveillance testing at $4.5 billion in the deal announcement. That figure is drawn from incidence and surveillance frequency in HPV-driven head, neck, and anal cancers, plus adjacent indications where TTMV-DNA testing has documented or plausible clinical utility. The number frames why CareDx is paying up for a $34 million revenue base. The acquirer is buying both the existing run rate and a position inside a category where penetration is still in the single digits relative to the patient pool that could plausibly receive serial monitoring.

The MRD diagnostics market is split between tumor-informed approaches, which require sequencing the patient’s primary tumor to design a personalized assay, and tumor-naive approaches, which use a fixed assay across all patients in a category. NavDx is tumor-naive, which lowers the cost per test and shortens turnaround time, though it is restricted to indications where a viral driver provides a uniform biomarker target. The HPV-driven cancers for which NavDx is positioned are the ideal substrate for that approach because virtually every HPV-positive tumor carries the same viral DNA signature.

Closing Conditions, Outside Date, and the 24-Hour Stockholder Consent

Closing is subject to expiration or termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting period, customary representations-and-warranties accuracy, and the absence of a Material Adverse Effect on Naveris between signing and close. The merger agreement defines Material Adverse Effect to include any event that would “prevent the Company from consummating the Transactions, or would be reasonably likely to materially delay or impede the consummation of the Transactions,” on top of the conventional business-and-results carve-out language.

The merger agreement specifies an October 28, 2026 outside date by which the transaction must close, with automatic extension under specified circumstances that the 8-K does not enumerate. The 8-K also discloses an unusual termination right reserved to CareDx: the acquirer can walk away if Naveris does not deliver the requisite written stockholder consent within 24 hours after execution of the Merger Agreement. That clause exists because Naveris is a private company with a relatively concentrated cap table, and CareDx wants to lock in stockholder approval before any public announcement window opens for shareholder dissent or counterbid solicitation. Naveris signed the merger agreement on April 28, 2026, so the consent had to be in hand by April 29.

The parties expect closing in the third quarter of 2026. Goldman Sachs is acting as exclusive financial advisor to CareDx, with Fenwick & West as legal counsel. J.P. Morgan Securities LLC is acting as exclusive financial advisor to Naveris, with Skadden, Arps, Slate, Meagher & Flom LLP as legal counsel.

The Strategic Pivot: From Transplant-Only to Specialty Oncology Adjacency

CareDx has been a transplant-diagnostics company for its entire history. Its core revenue line is the AlloSure and AlloMap testing portfolio for kidney, heart, and lung transplant patients. That franchise is concentrated, well-reimbursed, and growing, but it has finite addressable patient volume because the transplant population is small. The Naveris acquisition is the first time CareDx has acquired into a non-transplant indication. CEO John Hanna framed the rationale in the deal press release: “We are focused on being a leader in concentrated specialty markets where a high burden of disease drives repeat testing. Naveris fits that profile with a differentiated technology that is early in its adoption.”

The fit is structural. Both businesses sell molecular tests that produce serial results, both are paid largely through Medicare and commercial payers, and both depend on building reimbursement and clinical-evidence flywheels in a tight specialist community (transplant centers in CareDx’s case, head-and-neck cancer surgery and oncology in Naveris’s case). The commercial muscle of one can be plausibly extended into the other.

The risk is that specialty oncology is a different commercial channel than transplant. Transplant is concentrated in roughly 250 U.S. transplant centers; head-and-neck oncology is dispersed across hundreds of community and academic practices. Building reach into that channel requires a different sales footprint than the one CareDx has spent fifteen years building.

The Quarter Underneath the Deal

The same Form 8-K furnishes Item 2.02 Results of Operations and Financial Condition for CareDx’s first quarter 2026 ended March 31, 2026. Total revenue was $118 million, up 39 percent year over year. Testing services revenue was $91 million, up 48 percent, on approximately 54,900 tests, up 17 percent. GAAP net income was $3 million versus a $10 million loss in the prior-year quarter. Adjusted EBITDA was $19 million versus $5 million a year ago.

CareDx raised its full-year 2026 revenue guidance to a range of $447 million to $465 million, up from a prior range of $420 million to $444 million. Adjusted EBITDA guidance was raised to a range of $43 million to $57 million. Average revenue per test was approximately $1,660, including roughly $14 million of prior-period revenue that was recognized in the quarter as collections caught up.

The 8-K also confirms that CareDx’s previously announced divestiture of its Lab Products business to Eurobio Scientific for $170 million in cash remains in motion, and that the board of directors has authorized a common-stock repurchase program of up to $100 million over a 24-month window. Read together with the Naveris purchase, the story CareDx is telling its investors is a portfolio reshape: divest the lower-margin Lab Products line for cash, return some of that cash to shareholders, and redeploy capital into a specialty oncology adjacency where the unit economics resemble the testing-services business.

What to Watch

HSR clearance timing: The Hart-Scott-Rodino waiting period is 30 days from filing for cash-only acquisitions, extendable if the antitrust agencies issue a Second Request. A clean expiration would put closing on track for the third quarter. A Second Request would push the timeline materially later and signal the agencies see overlap concerns where the parties presented none.

The earnout disclosure when proxy-equivalent materials surface: The 8-K does not disclose the specific 2026 and 2027 revenue thresholds that trigger the $100 million in earnout payments. If a more detailed schedule appears in a subsequent 8-K/A or in CareDx’s next 10-Q footnotes, the implied management forecast for the Naveris business will become readable.

Sales-channel integration plan: CareDx will need to articulate, on its first-quarter earnings call and in subsequent quarters, how it intends to operate Naveris commercially. Whether the head-and-neck oncology call point gets covered by an integrated sales force, a standalone Naveris team, or a hybrid arrangement is the operating choice that will determine whether the 30-to-40 percent annual growth forecast holds.

The Medicare reimbursement landscape for tumor-naive MRD: NavDx has Medicare coverage today, but the broader category of MRD surveillance testing is in active policy development at the Medicare Administrative Contractors and CMS. Any change to the Local Coverage Determination structure for MRD testing would alter the economics of the acquired business.

Lab Products divestiture close: The $170 million Eurobio Scientific transaction is a separate moving piece. Closing of that deal is what will free the corresponding cash that funds part of the CareDx capital-allocation program and removes the lower-margin segment from the income statement going forward.

Take

This is a small bolt-on by absolute deal size, but it changes what CareDx is. A company that has been a single-franchise transplant-diagnostics business is now a two-franchise testing-services business with a specialty oncology leg. The structural fit is strong (the same payer channel, the same serial-testing economics, the same need to compound reimbursement and evidence) but the commercial fit is not free. Selling NavDx into head-and-neck oncology requires a sales footprint CareDx does not currently have. The earnout is the most important number in the deal even though the headline is the $160 million up-front check, because it tells you what CareDx thinks the business will do over the next twenty months and what it is willing to pay if Naveris hits those marks.